Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens

PURPOSE: To achieve reductions in infusion time, infusion sites, and frequency, a prospective, open-label, multicenter, Phase 3 study evaluated the safety, efficacy, and tolerability of subcutaneous immunoglobulin (SCIG) 16.5% (Cutaquig®, Octapharma) at enhanced infusion regimens. METHODS: Three sep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Sudhir, DeAngelo, James, Melamed, Isaac, Walter, Jolan E., Kobayashi, Ai-Lan, Bridges, Tracy, Sublett, J. Wesley, Bernstein, Jonathan A., Koterba, Alan, Manning, Michael, Maltese, Joanna, Hoeller, Sonja, Turpel-Kantor, Eva, Kreuwel, Huub, Kobayashi, Roger H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169187/
https://www.ncbi.nlm.nih.gov/pubmed/37160610
http://dx.doi.org/10.1007/s10875-023-01509-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169187/
https://www.ncbi.nlm.nih.gov/pubmed/37160610
http://dx.doi.org/10.1007/s10875-023-01509-4

Ejemplares similares